Enzene Biosciences is adding a new facility for continuous biomanufacturing in the US. Russell Miller, Vice President, Global Sales & Marketing, Enzene Biosciences, provided an update at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week. 

Enzene Inc., the US entity of Pune, India-based Enzene Bioscience, is building a new GMP manufacturing facility in New Jersey. The new Enzene site, built around the company’s proprietary EnzeneX technology, will provide continuous biomanufacturing.

The company has successfully identified, leased, and set up this inaugural manufacturing plant. The facility is 54,000 square feet and will be launched in three phases, with the Phase I launch date slated for the third quarter of 2024. The facility wil include GMP drug-substance capability with 500-L bioreactor (Phase 1), 2 KL bioreactor (Phase 2), and 500-L & 2-KL bioreactor (Phase 3). It will also include a drug-product manufacturing suite  with  formulation and small-volume filling equipment. The facility will also include a quality control lab, development lab, warehouse, freezer rooms, and cell bank store.